Introduction

Multidrug resistance among bacteria increases the need for new therapeutic options. Tigecycline is one candidate drug, due to property of a wider anti-bacterial spectrum to multi-drug resistant (MDR) pathogens. However, it has still not been approved for use in pediatric patients.

Methods

In this study the effectiveness and safety of tigecycline in children was assessed retrospectively.

Results

A total of 36 pediatric patients, received tigecycline therapy with a median of 13 days (2–32 days). Tigecycline was used as a combination therapy in all cases. Microbiological eradication was achieved in 27 patients (75%) and clinical response was observed in 30 patients (83%). There were six cases (17%) of relapse.

Conclusion

Our findings suggest that tigecycline may be an option for children with severe infections due to multidrug resistant bacteria.

中文翻译：

---

多药耐药菌血症儿科患者的替加环素治疗。

介绍

细菌之间的多药耐药性增加了对新治疗选择的需求。替加环素是一种候选药物，因为它对多重耐药 (MDR) 病原体具有更广泛的抗菌谱。然而，它还没有被批准用于儿童患者。

方法

本研究回顾性评估了替加环素在儿童中的有效性和安全性。

结果

共有 36 名儿科患者接受了中位数为 13 天（2-32 天）的替加环素治疗。在所有情况下，替加环素都被用作联合治疗。27 名患者 (75%) 实现了微生物根除，30 名患者 (83%) 观察到了临床反应。有 6 例 (17%) 复发。

结论

我们的研究结果表明，替加环素可能是因多重耐药菌导致严重感染的儿童的一种选择。